The DMD/MBA program is an integrative, four-year degree that combines business courses with the DMD curricula. Students start their business classes the summer before dentistry school. The remaining ...
Sarepta Therapeutics has temporarily suspended use of the gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy (DMD) after a second patient taking the drug died from acute ...
As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its Duchenne muscular dystrophy (DMD) therapy is up to the task. The latest ...
New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients "Seeing these promising results validates our ...
It’s the final nail in the coffin for Catabasis Pharmaceuticals’ Duchenne muscular dystrophy (DMD) hopeful as edasalonexent has once again failed to deliver. The results look like this: The phase 3 ...
Boston-based biotech PepGen Inc. (NASDAQ:PEPG) announced today it will discontinue all Duchenne muscular dystrophy (DMD) research after its lead candidate, PGN-EDO51, failed to achieve target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback